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Abstract
Background and aims: Variation in micro-RNA (miRNA) levels in blood has been associated 
with alterations of physiological functions of the cardiovascular system. Circulating miRNA have 
the potential to become reliable biomarkers for risk stratification and early detection of 
cardiovascular events. Recurrent thrombotic events in patients with established coronary artery 
disease (CAD) demonstrate the need for personalized approaches to secondary prevention, 
especially in light of recent novel treatment approaches.
Methods: In a single center cohort study, whole blood samples were collected from 437 subjects 
undergoing cardiac catheterization, who were followed for recurrent cardiovascular events during 
a mean follow up of 1.5 years. We selected a case cohort (n = 22) with recurrent thrombotic events 
on standard medical therapy (stent thrombosis (n = 6) or spontaneous myocardial infarction (MI) 
(n = 16)) and a matched cohort with CAD, but uneventful clinical follow up (n = 26), as well as a 
control group with cardiovascular risk factors, but without angiographic CAD (n = 24). We 
performed complete miRNA next generation sequencing of RNA extracted from whole blood 
samples (including leukocytes and platelets).
Results: A differential pattern of miRNA expression was found among controls, CAD patients 
with no events, and CAD patients with recurrent events. MiRNA previously associated with MI, 
CAD, endothelial function, vascular smooth muscle cells, platelets, angiogenesis, heart failure, 
cardiac hypertrophy, arrhythmia, and stroke were found variably expressed in our case-control 
cohorts. Seventy miRNA (FDR < 0.05) were linked to the risk of recurrent myocardial infarction 
and future stent thrombosis, as compared to CAD patients with subsequently uneventful follow up.
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Conclusions: MiRNA next generation sequencing demonstrates altered fingerprint profile of 
whole blood miRNA expression among subjects with subsequent recurrent thrombotic events on 
standard medical therapy (‘non-responders’), as compared to subjects with no recurrent 
cardiovascular events. MiRNA profiling may be useful to identify high risk subjects and provide 
additional insights into disease mechanisms not currently attenuated with standard medical therapy 
used in CAD treatment.
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1. Introduction
Coronary artery disease (CAD) remains the predominant cause of increased morbidity and 
mortality in the elderly American population [1]. Survival of patients has improved after 
myocardial infarction with rapid use of reperfusion and evolving coronary revascularization 
technologies during acute coronary syndromes, yet the rate of recurrent myocardial 
infarction remains ∼30% at 5 years despite optimal medical therapy [1]. Secondary 
prevention after myocardial infarction routinely consists of dual antiplatelet therapy with 
aspirin and a P2Y12 receptor inhibitor. While extended dual antiplatelet therapy reduces risk 
of recurrent events, it is not completely protective from events (5.8% recurrent risk of MI 
after 12 months in ticagrelor treated arm in PLATO trial), and it is associated with increased 
risk of bleeding [2]. There is a need for reliable and sensitive biomarkers that would reliably 
identify patients at increased risk for recurrent myocardial infarction and thrombotic events 
after initial diagnosis of CAD, to tailor preventive therapy.
MiRNAs are non-coding RNA (18–25 nucleotides) that are usually generated by cleaving of 
primary mRNA transcripts by ribonuclease III [3–5]. MiRNAs that are synthesized in the 
nucleus are transported into the cytoplasm to undergo a sequential modifications such as 
assembly into a dimer, tagging with a ribonuclear protein (RNP) and unwinding by a 
helicase to become fully functional [6–9].The most commonly function attributed to 
miRNAs is usually gene repression, but occasionally they can also be associated with gene 
up-regulation [6–10]. The mechanism of miRNAs induced transcriptional repression 
involves a wide variety of mechanisms like inhibition of initiation, elongation and 
degradation of nascent proteins by exolytic pathway [6–9]. MiRNA are believed to be a key 
system in gene regulation and are likely closely involved in changes related to common 
cardiovascular pathophysiology, and increasing data on relevance of variable miRNA 
expression in various presentations of cardiovascular disease and its risk factors has been 
published [8,11–14].
Most studies using miRNA as biomarkers have focused on circulating miRNA from plasma 
[15], while fewer studies have employed miRNA derived from fixed whole blood, which 
includes miRNA derived from platelets and leukocytes [16–18]. In concept, novel miRNA 
biomarkers may potentially be used to monitor effects of medical therapy on gene 
expression and posttranslational modifications. We hypothesized that distinctive miRNA 
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patterns would be identifiable and differentiate patient subsets between patients with and 
without recurrent events.
In this study, we performed miRNA sequencing of whole blood samples collected from a 
cohort of patients who underwent cardiac catheterization, who were followed prospectively 
for recurrent clinical events. We hypothesized that miRNA expression patterns may be 
distinct between patients with coronary artery disease who have uneventful clinical courses 
after initial diagnosis and management (i.e. ‘responders’ to conventional standard medical 
therapy), as compared to individuals with recurrent thrombotic coronary events, such as 
spontaneous myocardial infarction or stent thrombosis (‘non-responders’). We used next 
generation miRNA sequencing to obtain a complete human miRNA profile from selected 
subjects, as well as to avoid pre-emptive selection bias of specific target miRNA. Large scale 
miRNA profiling may help identify novel pharmacological gene targets important in 
secondary prevention of cardiovascular events in high risk patients with CAD, who are 
currently not adequately protected with standard medical therapy.
2. Materials and methods
The Krannert cardiac catheterization biobank (GENCATH) study is a prospective biobank 
study enrolling subjects undergoing cardiac catheterization at Indiana University.
The study protocol was approved by the Indiana University Institutional Review board. All 
subjects gave written informed consent prior to enrollment.
2.1. Study design
The complete GENCATH biobank cohort includes samples from 437 subjects who 
underwent cardiac catheterization. Inclusion criteria for the GENCATH biobank were 
coronary angiography or percutaneous coronary intervention (PCI) completed at one of the 
participating institutions (Indiana University Health Methodist and Eskenazi Health, 
Indianapolis, USA) during the index presentation. Exclusion criteria included age < 18 years 
and inability to provide informed consent. Clinical baseline variables were recorded at time 
of enrollment, including details of index coronary angiographic findings and index 
interventions. Subjects were prospectively followed with review of electronic medical 
records for occurrence of clinical events. Source coronary angiograms were reviewed to 
ascertain cases of stent thrombosis that occurred during follow up. From the GENCATH 
cohort we selected 72 subjects for complete miRNA sequencing profiling for use in a 
matched case-control analysis. The case cohort consisted of subjects with recurrent coronary 
thrombotic events (n = 22) (defined as either stent thrombosis (n = 6) or spontaneous 
myocardial infarction (n = 16)) after enrollment in the biobank. The CAD control cohort (n 
= 26) was a random matched group of patients with CAD and uneventful clinical follow up 
after enrollment in the biobank. A group of subjects with cardiovascular risk factors, but no 
diagnosis of heart failure, who underwent cardiac catheterization and had normal coronary 
arteries on angiogram was included as an additional control group (n = 24). The study 
design is summarized in Fig. 1.
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2.2. Blood samples
Whole blood was obtained by peripheral venipuncture or from arterial access sheaths and 
collected in PAXGENE blood RNA vacutainer tubes (Qiagen, MD, USA). Samples were 
obtained during the index hospitalization prior to cardiac catheterization and frozen at 
−80 °C until processing. Samples from patients with ST-elevation myocardial infarction on 
presentation were collected prior to hospital discharge. PAXgene® Blood RNA Tubes were 
thawed on ice and incubated at room temperature overnight. Total RNA including miRNAs 
was extracted using PAXgene® Blood miRNA Kit (Qiagen, Germantown, MD; Cat # 
763134) according to manufacturer’s instructions for manual purification of RNA from 
whole blood. Total RNA was quantified using Nanodrop (Thermo Fisher Scientific, 
Waltham, MA). The RNA quality and the amount of miRNA was measured using the 
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA).
2.3. MiRNA sequencing
10–20 ng of total RNA was used to create miRNA library. Total RNA samples with < 0.5% 
miRNA content was enriched for miRNAs. Library was prepared using the small RNA 
library preparation procedure in the Ion Total RNA-Seq Kit v2 User Guide, Pub. No. 
4476286 Rev. E (Life Technologies). If needed, a step of enrichment was conducted, 
following the small RNA library preparation procedure without smRNA enrichment in the 
Ion Total RNA-Seq Kit v2 User Guide, Pub. No. 4476286 Rev. E (Life Technologies). The 
mean RIN for the RNA samples was 8.1 (Min: 6.7, Max: 9.3). Each resulting barcoded 
library was quantified and its quality accessed, and the libraries pooled in equimolar 
concentrations. Eight microliters of 100 pM pooled libraries was applied to Ion Sphere 
Particles (ISP) for template preparation and amplification using Ion OneTouch 2. ISPs were 
loaded onto the Ion PI™ chip and sequenced on the Ion Proton semiconductor. Each PI chip 
generated approximately 50 million usable reads of 21–22bp miRNA fragments.
2.4. Bioinformatics analysis
The sequencing data in unmapped bam format generated from ion Proton instrument were 
first converted to fastq format with the SamToFastq function of Picard (https://
broadinstitute.github.io/ picard/). The data were then assessed for quality control with 
FastQC (v.0.11.4, Babraham Bioinformatics, Cambridge, UK). The Ion Torrent system 
applies several quality checks to the sequence reads before writing the reads out, this 
including removal of adapter sequence and low-quality 3’ ends. Therefore, adapter sequence 
trimming was not included in the analysis steps. The sequencing reads were mapped to the 
human genome (UCSC hg19) using STAR aligner (v.2.4.2) [19]with the following 
parameter: -outFilterMultimapNmax 50 –alignIntronMax 1 –outSAMmapqUnique 60”. 
Reads with mapping quality greater than 10 were assigned to mature miRNAs from mirBase 
hg19 v20 (www.mirbase.org) with htseq-count (HTSeq-0.6–1) [20]. Differential miRNA 
expression analysis was performed using edgeR (v.3.12.1) [21,22]. MiRNAs with read count 
per million (CPM) > 3 in more than 21 of the samples were used for the analysis. False 
discovery rate (FDR) was computed from p-values using the Benjamini-Hochberg 
procedure. Pathway analysis of the selected miRNA target genes were carried out with 
DAVID through the R package RDAVIDWebService [23–25].
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3. Results
3.1. Clinical characteristics and endpoints
The demographics and clinical variables of subjects enrolled in the GENCATH biobank 
cohort are described in Supplemental Table 1. The average age of subjects in the GENCATH 
biobank cohort is 56 years, with the majority of male gender. The majority of subjects 
(70.9%) had angiographic coronary artery disease, and the majority presented with acute 
coronary syndrome. Subjects in the GENCATH cohort were followed for a mean of 1.59 
± 1.1 years. Recurrent myocardial infarction occurred in 10.1%, unplanned PCI in 5.5%, 
unplanned CABG in 1.8%, stent thrombosis in 1.6%, cardiovascular death in 2.7%, and 
death in 5% of patients during follow-up.
Demographics and clinical variables of the matched coronary artery case-control cohorts 
selected from the biobank for miRNA sequencing are listed in Supplemental Table 2.
Subjects with recurrent myocardial infarction or stent thrombosis (recurrent events) were 
matched with control subjects with coronary artery disease and uneventful follow-up (no 
recurrent events). No significant difference was observed for age, gender, weight, co-
morbidities (diabetes mellitus, hypertension, hyperlipidemia, history of coronary artery 
bypass grafting, history of PCI, history of MI), risk factors (family history, smoking), P2Y12 
antiplatelet therapy, initial presentation, and PCI target vessels (Supplemental Table 2).
Demographics and clinical variables of subjects with coronary artery as compared to control 
group with angiographically normal coronary arteries is displayed in Supplemental Table 3. 
Subjects with diagnosis of congestive heart failure (CHF) were excluded from the control 
cohort, therefore CHF was only found in CAD group. The prevalence of diabetes mellitus, 
hyperlipidemia, and family history of premature coronary artery disease was higher in the 
CAD cohort as compared to controls without CAD.
3.2. MiRNA
With next generation sequencing, we identified 321 miRNA expressed in controls, CAD 
patients with recurrent events, and CAD patients with no events. Supervised hierarchical 
clustering of these 321 miRNA with heat maps demonstrated differential pattern of miRNA 
expression between CAD patients and controls, as well as among CAD patients with or 
without recurrent ischemic events (Figs. 2 and 3). The complete list of miRNAs that were 
upregulated and down-regulated in control, CAD patients with no recurrence and CAD 
patients with recurrent events are presented in table format in Supplementary Data 
(Supplementary Table 5 and 6).
We separated the miRNA on the basis of false discovery rate (FDR) < 0.05 and thus 
identified 70 miRNA that were significantly differentially expressed between CAD patients 
with recurrent events as compared to CAD patients with no events. Thirty seven miRNA 
were upregulated and 33 miRNA were specifically down-regulated in CAD patients who 
presented with recurrent myocardial infarction or stent thrombosis (recurrent events) as 
compared to CAD patients with uncomplicated follow-up (no events) (Fig. 4 & 
Supplemental Fig. 1). A review of the potential functional characteristics of these miRNA 
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revealed that many of the miRNAs that were differentially expressed have been associated 
with pathophysiologic changes or functions associated with cardiovascular disease state 
(Supplemental Table 4). Many miRNA (miR-19a-3p, miR-19b-3p, miR-21a-5p, 
miR-29c-3pmiR-30e-5, miR-144–5p, miR-148–3p, miR-152–3p, miR-190a-5p, miR-199–
5p, miR-320a, miR-423–3p, miR-424–5p, miR-433–3p, miR-451a, miR- 454–5p, miR-543, 
miR-590, miR-877–5p, miR-1292–5p, miR-2110, miR-3615, miR-7704) have been 
previously associated with coronary artery disease presentations (stable angina, unstable 
angina, and myocardial infarction). In addition, miRNA that were significantly altered 
among CAD patients with recurrent events have been previously associated with platelet 
function (miR-340–3p, miR-451a, miR-1976 and miR- 6734), endothelial function 
(miR-19b-3p, miR-106–3p, miR-185–3p and miR-589–5p), vascular smooth muscle 
proliferation (miR-29a-3p, miR- 143–3p, miR-152–3p and miR-589–5p), angiogenesis 
(miR-485–3p and miR-18a-3p), coronary artery calcification (miR-27a-3p, miR-29a-3p, 
miR-223 and miR-4745), atherosclerosis (miR-10a-5p, miR-27a-3p, miR-331–3p and 
miR-106b-3p), atrial fibrillation (miR-409–3p and miR- 7704), stroke (miR-15a-5p, 
miR-362–3p, miR-424–5p and miR-6857– 3p), heart failure (miR-19b-3p, miR-192–5p, 
miR-152–3p, miR-301–3p, miR-338–3p, miR-362–3p, miR-409–3p, miR-589–5p, 
miR-660–5p and miR-2110), cardiac hypertrophy (miR-101–3p,miR-152–3p,miR-181–3p 
and miR-185–3p) and hypertension (miR-27a-3p and miR-505–5p). For other miRNA, no 
previous associations with cardiovascular disease states have been published (e.g. miR-3653, 
miR-6750–3p, miR-6743–3p, miR-1976). In fact the miRNA with the most marked 
difference in expression between CAD subjects with recurrent events vs those with 
uneventful follow-up was miR-3653 (log2-fold change = −3.26; FDR = 0.0006), which has 
not previously been linked to specific disease states. There was only one miRNA 
significantly different among cohorts with CAD and no recurrent events vs. control group 
without CAD (miR-618, log2 fold change = 1.29; FDR = 0.03). In contrast, there were 3 
miRNA significantly different between CAD subjects with recurrent events vs. controls 
without CAD (miR-6087: FDR = 2.27*10−6; miR-3653: FDR = 2.62*10−6; miR-551a: FDR 
= 0.047).
We classified miRNAs that were upregulated and downregulated in our cohort groups 
according to previously described functional and clinical associations (Fig. 5).
3.3. Gene target pathway analysis
In total, 47 miRNA with p < 0.05 have not previously been associated with cardiovascular 
disease. We identified the gene targets of these 47 non-cardiovascular miRNAs with target 
scan, with target score less than 80. Furthermore, pathway analysis of the selected miRNA 
target genes was carried out with DAVID through the R package RDAVIDWebService [23–
25]. The methodology and pathway analysis of non-cardiovascular mRNAs identified in this 
study are included in Supplemental Data section (Supplemental files). The dot plots for the 
DAVID GO pathway analysis are viewable in the Supplemental Data. They were separated 
into the three categories of GO analysis (BP, CC and MF). Only pathways with an adjusted 
p-value < 0.05 were plotted; and only the top 20 were plotted if there are more than 20 
enriched pathways for a specific miRNA. No plot was generated if a miRNA has no 
enriched pathways with an adjusted p-value < 0.05.
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4. Discussion
The goal of our study was to examine whole blood next generation miRNA sequencing for 
use as biomarker fingerprint and in the identification of subjects with coronary artery 
disease, who are at increased risk for recurrent events with current standard medical therapy. 
In particular, we focused on patients with established coronary artery disease, who after 
enrollment in the study, suffered from either coronary stent thrombosis or spontaneous 
myocardial infarction on standard medical therapy. A random cohort of subjects with 
coronary artery disease and uneventful follow up served as control, as did a cohort of 
subjects with normal coronary arteries on angiography. We demonstrated that miRNA 
sequencing provided a ‘fingerprint’ snapshot that was markedly different in subjects with 
subsequent recurrent thrombotic events compared to those without events. In particular, 
subjects with subsequent coronary stent thrombosis exhibited markedly altered miRNA 
expression as compared to subjects without events (Fig. 2).
There was no significant difference in prevalence of clinical variables in subjects with CAD 
and recurrent thrombotic events compared to subjects without events. As expected, subjects 
with angiographically normal coronary arteries in our control cohort were younger, had 
fewer cardiovascular risk factors, and no congestive heart failure. Whole blood miRNA 
sequencing also demonstrated altered miRNA expression profiles between coronary artery 
disease subjects without events and subjects with normal coronary arteries. The large 
number of miRNA with significantly differential expression among subjects with CAD and 
uneventful follow up compared to those with recurrent events (70 miRNA with FDR < 0.05) 
illustrates that although subjects were quite evenly matched based on classic clinical 
variables used to predict post PCI risk, there appear to be substantial metabolic and 
epigenetic differences among patient subgroups with increased incidence of recurrent 
cardiovascular events.
Various miRNAs have been described in the literature as biomarkers in blood plasma for 
early detection and treatment of stable angina, unstable angina and myocardial infarction. 
Up-regulation of miR-1, miR-126 and miR-485, and miR-133 in plasma was considered to 
be an indicator of stable and unstable angina compared to control patients [26–28]. Increases 
in the plasma levels of miR-208-a/b, miR-499–5p, miR-1 and miR-133 were associated with 
the onset of MI [27,29,30]. Other miRNA were associated with premature cardiac death or 
ventricular arrhythmias in MI patients (miR-155, miR-380, miR151–5p) [31,32]. Consistent 
with several of these findings, we found a differential pattern of expression of miRNAs 
related to MI disease states that were upregulated and downregulated in patients with 
recurrent coronary events compared to patients with no events in our cohorts.
Previously described mechanisms linking miRNA function to coronary artery disease 
phenotypes include downregulation of phospho-AKT/Nitric oxide synthase pathway 
(miR-206), downregulation of VEGR (miR-361–5p, miR-221, miR-222), promotion of early 
senescence (miR-217, miR-34), disorganization of cell cycle replication (miR-503, miR-93), 
or downregulation of monocyte chemoattractant protein-1 (miR-22) [33–37]. However, these 
specific miRNA were not significantly differentially expressed among cohorts in our study.
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A surprising number of miRNA differentially expressed among subjects with subsequent 
recurrent thrombotic coronary events were previously linked to alterations in endothelial 
function, platelet function, inflammation, coagulation, or smooth muscle proliferation, 
which are likely important mediators leading to coronary thrombosis. MiR- 126–3p is highly 
expressed in endothelial cells and platelets and while its function in the endothelium has 
been well elucidated, its function in platelets has remained largely unknown. Kaudewitz et 
al. have demonstrated that mice knockout for miR-126–3p had reduced platelet aggregation. 
In addition, P2Y12 receptor expression has also been reduced in whole blood of antagomir 
126–3p treated mice [38]. In our study, miR-126–3p was significantly upregulated, in 
patients with recurrent disease vs. controls, as well as in patients with recurrent disease vs. 
stable CAD. The overexpression of miR-126–3p in platelets of patients with recurrent 
cardiac events could potentially be linked to either increased tendency towards platelet 
aggregation or to less response to antiplatelet agents, particularly via the P2Y12 pathway. 
MiR-223 deficient mice have been shown to form large thrombi and have increased 
aggregation tendency in response to collagen [38], yet in our study, miR-223 was shown to 
be upregulated in patients with recurrent events compared to stable disease.
Various miRNA have also been implemented in inflammatory states associated with 
atherosclerosis leading to cardiac events. MiR-451 and miR-454 were previously reported to 
be over-expressed in the platelets of patients with CAD [39] and miR-454 has been linked to 
production of inflammatory cytokines as a part of the thrombus formation cascade. Both of 
the aforementioned miRNAs are upregulated in our study in the recurrent event group 
compared to stable disease. Yet miRNA-10p, which has been previously shown to be 
suppressed in athero-susceptible regions of swine aortas [40] and favored to be a post-
translational modulator of the pro inflammatory NF-κB pathway, was up-regulated in our 
study in patients with recurrent events vs. stable disease. Interestingly though, it was as 
expected down-regulated in patients with CAD vs. controls. Many inflammatory cytokines 
have been involved in atherosclerosis including TNF alpha. MiR-19b, which is a part of 
miR- 17–92 cluster, has been found to be an important modulator of the TNF alpha pathway 
and its down-regulation in patients with CAD has been shown to increase the inflammatory 
background in patients with coronary disease [35]. In our study, expectedly, miR-19b was 
down-regulated in stable CAD compared to controls, yet when looking at recurrent disease 
vs. stable disease, miR-19b expression is paradoxically upregulated.
MiR-3653 was the most significantly down-regulated miRNA in our dataset in comparison 
with recurrent events vs. controls. It has numerous predicted targets, but has not been 
previously linked to cardiovascular disease in the published literature.
Many other miRNA have been previously found differentially expressed in subjects with 
myocardial infarction, angina, stroke, congestive heart failure, cardiac hypertrophy, and 
arrhythmias. We have summarized previous reports in the literature of the specific miRNA 
that were also found to be differently expressed between cohorts in our study in 
Supplemental Table 4.
The large number of novel miRNA found differentially expressed in sequencing from whole 
blood samples stabilized in PAXGENE RNA tubes in our cohort, suggests that miRNA 
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derived from leukocytes and platelets may have contributed to differential expressions 
patterns. This is particularly noteworthy, as most other studies examining the use of miRNA 
profiling in diagnosis of CAD phenotypes have used plasma samples, which do not contain 
miRNA derived from leukocytes or platelets, other than the miRNA that were released into 
plasma in vivo or during sample preparation. The differential expression of miRNA in our 
study could have been influenced by changes in expression levels at the cellular level or by a 
modified cellular composition of whole blood. In addition, previous studies using miRNA 
have focused on the correlation of miRNA with cardiovascular risk factors and disease 
subtypes, but have not focused on the use of miRNA profiling to identify subjects at risk of 
subsequent thrombotic events on standard medical therapy. Current evidence based medical 
therapy for secondary prevention of CAD has substantially lowered event rates with use of 
dual antiplatelet therapy, high intensity statins, angiotensin converting enzyme inhibitors, 
beta-blockers, and aldosterone antagonists after MI, however, one year recurrent myocardial 
infarction event rates in most recent ACS trials remain at ∼5%. This suggests that a 
substantial subset of patients with CAD are not adequately protected with standard medical 
therapy, and miRNA profiling of cohorts of subjects with ‘therapy failure’ may potentially 
lead to novel therapeutic targets in the treatment of cardiovascular disease. We have 
performed pathway analysis of all novel miRNA not previously associated with 
cardiovascular disease, and the results are included in the Supplemental Data files.
Future studies are needed to explore the clinical utility and applicability of large datasets 
derived from miRNA sequencing in care of patients with coronary artery disease, including 
limitations of applying classic single biomarker models to miRNA ‘fingerprints’.
4.1. Limitations
There are several limitations to our study. The study sample size was relatively small, so we 
cannot generalize the results of the study, and we did not replicate the findings in a separate 
cohort. Moreover, the specific source and sequential downstream signaling events that lead 
to production of these miRNA in patients with recurrent CAD events are unknown. Some of 
the blood samples, particularly from STEMI patients, were collected after heparin 
administration, which could have altered some of the miRNA expression. Lastly, we did not 
investigate temporal changes in miRNA profiles that may occur in individual patients over 
time in response to medical therapy or disease evolution, and may affect utility in risk 
prediction.
4.2. Conclusions
In conclusion, our study suggests that whole blood miRNA sequencing may provide an 
epigenetic, metabolic fingerprint of disease risk in patients with coronary artery disease. In 
specific, a large number of miRNA were differentially expressed in whole blood in subjects 
with subsequent coronary thrombotic events compared to subjects with uneventful clinical 
course on standard therapy. The miRNA found to be differentially expressed among subjects 
with subsequent events in our study, may potentially serve as indicators for genes involved 
in disease modulation in subjects with disease refractory to current therapy. Many of the 
miRNA found to be variably expressed in patients with recurrent MI or stent thrombosis in 
our study were previously linked to MI, endothelial function, platelet function, coagulation, 
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and inflammation. Further investigation exploring the biologic effects of established key 
miRNA and novel miRNA variants is needed. Distinct patterns between different groups of 
patients with coronary artery disease suggest utility in monitoring progression and 
quiescence of coronary artery disease by measurement of whole blood miRNA profiles, 
beyond classic biomarkers or ‘simple’ clinical disease classifications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• miRNA next generation sequencing performed in CAD patients with and 
without recurrent events and controls.
• Differential miRNA expression pattern between controls, CAD patients with 
no events, and CAD patients with recurrent events.
• Seventy miRNA (FDR < 0.05) were linked with risk of recurrent myocardial 
infarction and future stent thrombosis.
• MiRNA profiling may identify high risk subjects and provide insights into 
CAD disease mechanisms.
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Fig. 1. 
Study flow chart.
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Fig. 2. 
Heat map of the expression profiles of the miRNA array analysis of 22 coronary artery 
disease patients with recurrent coronary events (blue) and 26 patients with no recurrent 
thrombotic coronary events (red).
Subjects with stent thrombosis during follow up are identified. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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Fig. 3. 
Heat map of the expression profiles of the miRNA array analysis of 48 coronary artery 
disease patients (blue) and 24 controls without coronary disease on angiography (yellow).
Differences in miRNA expression in CAD patients with recurrent thrombotic events vs. 
CAD patients with no recurrent events. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.)
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Fig. 4. 
Expression pattern of circulating distinct miRNA levels in blood samples of patients 
undergoing cardiac catheterization.
Next generation miRNA sequence analysis of miRNA of whole blood samples of subjects 
with coronary disease and recurrent events and subjects with coronary disease and no 
recurrent events with false discovery rate of < 0.05. The log fold 2 changes of CAD cases 
with recurrent and non-recurrent events were plotted and shown in the graph.
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Fig. 5. 
MiRNA differentially expressed in CAD patients with recurrent events vs. no-recurrent 
events and previously published associations.
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